Population pharmacokinetics of a triple‐secured fibrinogen concentrate administered to afibrinogenaemic patients: Observed age‐ and body weight‐related differences and consequences for dose adjustment in children

Abstract

Dosing in patients ≥40 kg based on the previous empirical finding using noncompartmental analysis where FC 1 g kg^-1 raises the plasma fibrinogen activity by 23 g L^-1 was confirmed. In patients <40 kg, (covering the age range from birth up to about 12 years old) FC 1 g kg^-1 raises the plasma fibrinogen by 19 g L^-1 . Dosing should be adapted accordingly unless therapy is individualized.